Original paperAnalysis of P-glycoprotein expression in osteosarcoma
References (24)
- et al.
An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugs in vitro
Biochim Biophys Acta
(1992) - et al.
Expression of MDR1 and GST-π in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness
Ann Oncol
(1992) - et al.
Expression of the MDR1 gene in bone and soft tissue sarcomas of adult patients
Eur J Cancer
(1993) - et al.
Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues
Ann Oncol
(1990) - et al.
The direct activation of human multidrug resistance gene (MDR1) by anticancer agents
Biochem Biophys Res Commun
(1989) Principles of chemotherapy
- et al.
Biochemistry of multidrug resistance mediated by the multidrug transporter
Annu Rev Biochem
(1993) - et al.
Mechanisms and clinical significance of multidrug resistance
Oncology
(1988) - et al.
Expression of a multidrug resistance gene in human cancers
J Natl Cancer Inst
(1989) - et al.
P-Glycoprotein in human sarcoma: evidence for multidrug resistance
J Clin Oncol
(1987)
Expression of a multidrug-resistance gene in human tumors and tissues
Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood
J Clin Oncol
Cited by (47)
Genomic and proteomic profiling of osteosarcoma
2021, Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to BedsideRole of ATP-binding cassette transporters in cancer initiation and progression
2020, Seminars in Cancer BiologyCitation Excerpt :Some of these studies also include information on associations between P-gp expression and tumor characteristics. P-gp expression evaluated in 105 cases of primary and metastatic osteosarcoma was detected in 23% of primary and in 50% of metastatic lesions [200]. Increased P-gp levels were observed in 44% of the patients with osteosarcoma before treatment, particularly in those with tumors greater than or equal to 10 cm in size (60%) or with tumors associated with metastatic disease (100%) [201].
ABCG1 and Pgp identify drug resistant, self-renewing osteosarcoma cells
2019, Cancer LettersCitation Excerpt :One mechanism of acquired MDR is the overexpression of ABC transporter proteins, such as p-glycoprotein (Pgp, ABCB1), which induce MDR through the active efflux of chemotherapeutic agents from cells to reduce the efficacy of the treatment and enabling cell survival. In OST, high expression of Pgp has been linked with a worse disease progression [15–18]. Cells with an aggressive MDR metastatic phenotype have been described in a variety of cancers [19–25], including OST [26–29] and are often referred to as cancer stem-like cells (CSCs).
Gene and proteomic profiling of osteosarcoma
2015, Bone Cancer: Primary Bone Cancers and Bone Metastases: Second EditionPrognostic factors in localized extremity osteosarcoma: A systematic review
2009, European Journal of Surgical OncologyCitation Excerpt :The newly reported factors are mostly “indirect” factors, like protein expression in serum or genetic imbalances of tumor tissue. Most promising among these seem to be the high expression of p-glycoprotein,11,42–47 expression of the human epidermal growth factor receptor 2 (HER2),10,48–51 expression of vascular endothelial growth factor (VEGF),38,52–54 and loss of heterogeneity of the Rb-gene.55 It is possible that some of these factors may be of true predictive value, but it is important to keep in mind that the majority of these studies had methodological flaws.
Proteins expressed in osteosarcoma and serum levels as prognostic factors
2001, International Journal of Biochemistry and Cell Biology